Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Vasiliki Panou(University of Southern Denmark), Jane E. Churpek(University of Wisconsin–Madison), Oluf Dimitri Røe(Norwegian University of Science and Technology), Zejuan Li(University of Chicago), Madison Weatherly(nLIGHT (United States)), Arpita Desai(University of California, San Francisco), Arthur Wolin(University of Colorado Anschutz Medical Campus), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Viswateja Nelakuditi(University of Chicago), Kiran K. Turaga(Yale New Haven Hospital), Nanna Sulai(nLIGHT (United States)), Emily Skarda(nLIGHT (United States)), Sabah Kadri(nLIGHT (United States)), Shannon R. Zhang(nLIGHT (United States)), Lauren L. Ritterhouse(Brigham and Women's Hospital), Buerkley Rose(nLIGHT (United States)), Meghana Gadiraju(University of Chicago), Caroline Weipert(Guardant (United States)), Maria Helgeson(nLIGHT (United States)), Aliya N. Husain(University of Chicago), Hedy L. Kindler(University of Chicago), Jeremy P. Segal(University of Chicago Medical Center), David S. Fischer(Broad Institute), Amy Knight Johnson(nLIGHT (United States)), Dezheng Huo(University of Chicago Medical Center)
Cited by 229
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Squidpy: a scalable framework for spatial omics analysis
|Nature Methods|2022|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835